Results 141 to 150 of about 3,280,665 (275)
Botulinum Toxin for First Bite Syndrome: A Symptom‐Guided “Follow‐The‐Pain” Injection Strategy
ABSTRACT Background To evaluate botulinum toxin type A (BoNT‐A) for First Bite Syndrome (FBS) and assess a symptom‐guided “Follow‐the‐Pain” (FTP) injection strategy in patients with incomplete response to standard treatment. Methods Consecutive patients with postoperative FBS were treated with ultrasound‐guided intraparotid BoNT‐A injection.
Rosario Marchese‐Ragona +5 more
wiley +1 more source
ABSTRACT Introduction Cancer cachexia is characterized by skeletal muscle loss, poor nutrition, and systemic inflammation and is common in head and neck cancer. We evaluated whether the Cachexia Index (CXI) predicts treatment toxicity and survival in HPV‐negative HNSCC.
Gianluca Savoia +11 more
wiley +1 more source
ABSTRACT Cancer survivors frequently experience cancer‐related cognitive impairment (CRCI), but the contributions of different anti‐cancer therapies remain unclear. Patients with breast or gynaecological cancer were recruited before any anti‐cancer treatment.
Qiqi Lei +5 more
wiley +1 more source
Persistent symptom burden in long-standing systemic lupus erythematosus: a subgroup-focused hypothesis for an SLE-ME/CFS research phenotype. [PDF]
Habermann-Horstmeier L.
europepmc +1 more source
Abstract Objective Heavy menstrual bleeding is one of the most common gynecologic disorders among women of reproductive age and has a significant impact on their physical, psychological, and social well‐being. Although international guidelines recommend medical therapy as the first‐line treatment, it may prove ineffective, poorly tolerated, or ...
Jonas Rudaitis +3 more
wiley +1 more source
Integrated approach to menopausal hormone therapy in women with cardiovascular risk factors or established ischemic heart disease, from early treatment initiation and risk stratification to individualized therapy, multidisciplinary follow‐up, and health‐system recommendations.
Chiara Benedetto +9 more
wiley +1 more source
Abstract Background Medullary thyroid cancer (MTC) standard of care includes multikinase inhibitors (MKIs), which can exacerbate disease‐related diarrhea, primarily because of non‐RET kinase inhibition. We report diarrhea and other patient‐reported outcomes (PROs) with selpercatinib, a highly selective RET inhibitor, among patients with RET‐mutant MTC ...
Lori J. Wirth +10 more
wiley +1 more source
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li +29 more
wiley +1 more source

